- Home
- Jakavi 20 mg Tablet
Jakavi 20 mg Tablet Substitute
Jakavi 20 mg Tablet Substitute
Verified Ingredients and Effects
Composition:
RUXOLITINIB-20MG
Uses:
Jakavi 20 mg Tablet is used in the treatment of Myelofibrosis, polycythaemia vera (PV), and graft-versus-host disease (GVHD). The detailed uses of Jakavi 20 mg Tablet are as follows:<br/>• Treat myelofibrosis (MF): Jakavi 20 mg Tablet is used for intermediate or high-risk primary myelofibrosis, post-polycythemia vera MF, and post-essential thrombocythemia MF. It helps reduce spleen size and alleviate symptoms like fatigue and bone pain.<br/>• Manage polycythemia vera (PV): Jakavi 20 mg Tablet is used for patients who are intolerant to or have an inadequate response to hydroxyurea. It controls elevated red blood cell counts and reduces thrombotic risk.<br/>• Treat graft-versus-host disease (GVHD): Jakavi 20 mg Tablet is used in steroid-refractory acute and chronic GVHD in patients aged 12 years and older. It suppresses immune overactivity and reduces inflammation.<br/>
Medicinal Benefits:
Jakavi 20 mg Tablet belongs to the group of medicines called kinase inhibitors indicated in the treatment of myelofibrosis and polycythaemia vera in adults. It is also used to treat graft-versus-host disease in adults and children above 12 years of age. Jakavi 20 mg Tablet contains Ruxolitinib, which works by blocking the action of Janus-associated kinase enzymes, reduces the size of the spleen in patients with myelofibrosis and relieves symptoms like fever, bone pain, night sweats, and weight loss. Jakavi 20 mg Tablet selectively blocks enzymes called Janus Associated Kinases (JAK1 and JAK2); this helps relieve the symptoms, reduce spleen size and the volume of red blood cells produced in patients with polycythaemia vera, thus potentially reducing the risk of serious blood or vascular complications. Jakavi 20 mg Tablet reduces signs and symptoms of the acute and chronic forms of graft-versus-host disease, leading to disease improvement and survival of the transplanted cells.
FAQs
Jakavi 20 mg Tablet is used to treat Myelofibrosis, polycythaemia vera (PV), and graft-versus-host disease (GVHD).
Jakavi 20 mg Tablet helps treat myelofibrosis and polycythaemia vera by blocking the signals that cause cancer cells to multiply. It helps treat graft-versus-host disease by blocking the signals of the cells that cause GVHD.
Jakavi 20 mg Tablet may decrease your ability to fight infections and increase the risk of serious infection. Consult the doctor if you develop signs of infection such as fever, chills, sweats, sore throat, cough, sore, or frequent/urgent/painful urination.
Do not start a new medicine, including prescription medicines, non-prescription medicines and herbal or supplement medicines, whilst on treatment with Jakavi 20 mg Tablet without consulting your doctor.
Jakavi 20 mg Tablet may increase the risk of developing tuberculosis (TB), particularly if you are already infected with TB but do not have any symptoms. Inform the doctor if you have had TB or if you experience symptoms of TB like cough, cough with blood or mucus, weight loss, weakness or tiredness, loss of appetite, chills, fever, or night sweats.
